AKR1A1 consists of 325 amino acids and weighs 36573Da. The tertiary structure consists of a beta/alpha-barrel, with the coenzyme-binding site located at the carboxy-terminus end of the strands of the barrel.Alternative splicing of this gene results in two transcript variants encoding the same protein.
AKR1A1 gene is found highly expressed in kidney and liver, and moderately expressed in cerebrum, small intestine and testis. Small amounts of AKR1A1 are present in lung, prostate and spleen. However, it is not observed in heart or skeletal muscle. AKR1A1 belongs to the AKR superfamily, which are predominantly monomeric, soluble, NADPH-dependent oxidoreductases involved in the reduction of aldehydes and ketones into primary and secondary alcohols. AKR1A1 is shown to demonstrate characteristically high specific activity towards many aromatic and aliphatic aldehydes, and preferentially catalyses the NADPH-dependent reduction of aliphatic aldehydes, aromatic aldehydes and biogenic amines. It is also reported to be involved in the metabolism of 4-hydroxynonenal and play a role in the resistance to oxidative stress.
A SNP in intron 5 of AKR1A1 has been found to be significantly associated with increased risk of non-Hodgkin's lymphoma. AKR1A1 could activate procarcinogens, such as polycyclic aromatic hydrocarbon. AKRs have been linked to metabolism of the anthracyclinesdoxorubicin (DOX) and daunorubicin (DAUN), allelic variants showed significantly reduced metabolic activities, and hence these allelic variants can possibly act as genetic biomarkers for the clinical development of DAUN-induced cardiotoxicity.
^Bohren KM, Bullock B, Wermuth B, Gabbay KH (June 1989). "The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases". The Journal of Biological Chemistry. 264 (16): 9547–51. PMID2498333.
^Fujii J, Hamaoka R, Matsumoto A, Fujii T, Yamaguchi Y, Egashira M, Miyoshi O, Niikawa N, Taniguchi N (Jul 1999). "The structural organization of the human aldehyde reductase gene, AKR1A1, and mapping to chromosome 1p33-->p32". Cytogenetics and Cell Genetics. 84 (3-4): 230–2. doi:10.1159/000015265. PMID10393438.
^ abLan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, Holford TR, Leaderer B, Boyle P, Chanock S (April 2007). "Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma". Human Genetics. 121 (2): 161–8. doi:10.1007/s00439-006-0288-9. PMID17149600.
^El-Kabbani O, Green NC, Lin G, Carson M, Narayana SV, Moore KM, Flynn TG, DeLucas LJ (November 1994). "Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications". Acta Crystallographica Section D. 50 (Pt 6): 859–68. doi:10.1107/S0907444994005275. PMID15299353.
^Feather MS, Flynn TG, Munro KA, Kubiseski TJ, Walton DJ (May 1995). "Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase". Biochimica et Biophysica Acta. 1244 (1): 10–6. doi:10.1016/0304-4165(94)00156-r. PMID7766643.
^Bohren KM, Page JL, Shankar R, Henry SP, Gabbay KH (December 1991). "Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262". The Journal of Biological Chemistry. 266 (35): 24031–7. PMID1748675.
^ abLi D, Zhang Q, Zhou L, Liu R (March 2013). "[Effect of AKR1A1 knock-down on H2;O2; and 4-hydroxynonenal-induced cytotoxicity in human 1321N1 astrocytoma cells]". Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology. 29 (3): 273–6. PMID23643085.
^ abBains OS, Takahashi RH, Pfeifer TA, Grigliatti TA, Reid RE, Riggs KW (May 2008). "Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin". Drug Metabolism and Disposition. 36 (5): 904–10. doi:10.1124/dmd.107.018895. PMID18276838.
Tanimoto T, Ohta M, Tanaka A, Ikemoto I, Machida T (1991). "Purification and characterization of human testis aldose and aldehyde reductase". The International Journal of Biochemistry. 23 (4): 421–8. doi:10.1016/0020-711X(91)90169-N. PMID1901806.
Vander Jagt DL, Hunsaker LA, Robinson B, Stangebye LA, Deck LM (July 1990). "Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms". The Journal of Biological Chemistry. 265 (19): 10912–8. PMID2113526.
Wermuth B, Omar A, Forster A, di Francesco C, Wolf M, von Wartburg JP, Bullock B, Gabbay KH (1987). "Primary structure of aldehyde reductase from human liver". Progress in Clinical and Biological Research. 232: 297–307. PMID3615425.
Barski OA, Gabbay KH, Grimshaw CE, Bohren KM (September 1995). "Mechanism of human aldehyde reductase: characterization of the active site pocket". Biochemistry. 34 (35): 11264–75. doi:10.1021/bi00035a036. PMID7669785.
Takahashi M, Lu YB, Myint T, Fujii J, Wada Y, Taniguchi N (January 1995). "In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites". Biochemistry. 34 (4): 1433–8. doi:10.1021/bi00004a038. PMID7827091.
Robinson B, Hunsaker LA, Stangebye LA, Vander Jagt DL (December 1993). "Aldose and aldehyde reductases from human kidney cortex and medulla". Biochimica et Biophysica Acta. 1203 (2): 260–6. doi:10.1016/0167-4838(93)90092-6. PMID8268209.
Sato S, Lin LR, Reddy VN, Kador PF (August 1993). "Aldose reductase in human retinal pigment epithelial cells". Experimental Eye Research. 57 (2): 235–41. doi:10.1006/exer.1993.1119. PMID8405190.
Udovikova EA, Wojtczak L (May 1998). "Mitochondrial aldehyde reductase: identification and characterization in rat liver and kidney cortex". The International Journal of Biochemistry & Cell Biology. 30 (5): 597–608. doi:10.1016/S1357-2725(97)00143-X. PMID9693960.
Barski OA, Gabbay KH, Bohren KM (September 1999). "Characterization of the human aldehyde reductase gene and promoter". Genomics. 60 (2): 188–98. doi:10.1006/geno.1999.5915. PMID10486210.
Picklo MJ, Olson SJ, Markesbery WR, Montine TJ (July 2001). "Expression and activities of aldo-keto oxidoreductases in Alzheimer disease". Journal of Neuropathology and Experimental Neurology. 60 (7): 686–95. doi:10.1093/jnen/60.7.686. PMID11444797.
Laclau M, Lu F, MacDonald MJ (September 2001). "Enzymes in pancreatic islets that use NADP(H) as a cofactor including evidence for a plasma membrane aldehyde reductase". Molecular and Cellular Biochemistry. 225 (1-): 151–60. doi:10.1023/A:1012238709063. PMID11716357.
El-Kabbani O, Green NC, Lin G, Carson M, Narayana SV, Moore KM, Flynn TG, DeLucas LJ (November 1994). "Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications". Acta Crystallographica Section D. 50 (Pt 6): 859–68. doi:10.1107/S0907444994005275. PMID15299353.
Bohren KM, Brownlee JM, Milne AC, Gabbay KH, Harrison DH (May 2005). "The structure of Apo R268A human aldose reductase: hinges and latches that control the kinetic mechanism". Biochimica et Biophysica Acta. 1748 (2): 201–12. doi:10.1016/j.bbapap.2005.01.006. PMID15769597.